Correction to: BMC Infectious Diseases (2022) 22:563 https://doi.org/10.1186/s12879-022-07526-9
Following the publication of the original article [1], the authors identified that some symbols were absent in the on-line version of Figs. 4 and 5. These Figures have been corrected.
MDW depends on MIS-C severity and changes through the course of MIS-C diagnosis, treatment, and recovery. A Higher MDW values in MIS-C patients who manifested cardiac complications (Cardiac MIS-C) compared to children with MIS-C without cardiac involvement or presenting with symptoms concerning MIS-C (fever plus recent/current positive SARS-CoV2 PCR or SARS-CoV2 antibodies positive). B ROC in the validation cohort to assess the utility of MDW as a screening tool for cardiac involvement of MIS-C. AUC = area under the curve (fraction). C Blood from children with MIS-C was collected at multiple time points. MDW was plotted by time of collection: at admission, during hospital course, and at discharge or follow-up. Analysis by one way ANOVA. **P < 0.01, ****P < 0.0001. D MDW values from individual patients with MIS-C are plotted over the course of their illness. Black lines connect individual patients with MIS-C. Not all patients provided blood samples at each time point
Assessment of other hematological parameters in MIS-C. Hematologic parameters, including A white blood cell (WBC), B neutrophil (PMN), C lymphocyte, D monocyte, and E platelet counts were compared between healthy controls, children with non-infectious illness, children with an infectious/inflammatory illness, and children with MIS-C in the validation cohort. Analysis by ordinary one-way ANOVA. ns = non-significant, * P < 0.05, ** P < 0.01, *** P < 0.001. F Receiver operator curve of each hematologic parameter in MIS-C compared to values obtained from children presenting for medical care for infection/inflammatory or non-infectious illness
The original article has been corrected.